Dr. Devinsky oversees the development of innovative botanical drugs targeting neurological and mental health disorders. Renowned for his expertise in neurology, autism, epilepsy, and psychiatry, Dr. Devinsky has been at the forefront of groundbreaking research, serving as the principal investigator for Epidiolex™—the first FDA-approved cannabis-based drug developed by GW Pharmaceuticals and acquired by Jazz Pharmaceuticals for $7.2B. His work has earned him recognition on 10 patents related to the use of cannabidiol (CBD) in treating epilepsy. Also, Dr. Devinsky has published more than 700 peer-reviewed articles. His leadership at Ajna BioSciences is instrumental in advancing clinical trials and ensuring the highest standards of safety and efficacy in botanical medicine. Dr. Devinsky's commitment to integrating natural therapies into mainstream healthcare continues to drive significant advancements in the field.